Drug Interactions With Risk of QT-prolongation in a General Hospital
NCT ID: NCT02043912
Last Updated: 2014-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
222 participants
OBSERVATIONAL
2013-07-31
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Haloperidol Prophylaxis in Older Emergency Department Patients
NCT01530308
PROfylactic Haloperidol in Patients Defined as High Risk for DElirium With Delirium Risk mOdel
NCT03199950
Pharmacovigilance in Gerontopsychiatric Patients
NCT02374567
Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation
NCT03110900
A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room
NCT00457366
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Target population: Patients with haloperidol treatment
The following aspects will be investigated:
* The medication profiles will be checked for drug interactions with risk of QT-prolongation.
* Clinical risk factors for developing QT-prolongation (gender, age, (history of) cardiovascular disease, comorbidity,...) and lab results will be collected.
* Safety measurements (e.g. ECG) will be documented.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients treated with haloperidol
Haloperidol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Haloperidol
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Agentschap voor Innovatie door Wetenschap en Technologie
OTHER
KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eline Vandael
PhD-student
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eline Vandael, PhD-student
Role: PRINCIPAL_INVESTIGATOR
KU Leuven
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitair Ziekenhuis Leuven
Leuven, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EV002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.